Optimi Health Corp. has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in psychedelic-assisted therapy.

The LOI outlines Optimi's commitment to supplying its GMP natural psilocybin extract to ATMA's Phase II Psilocybin Clinical Trial, featuring Group and Individual Set and Setting protocols. The parties will work towards finalizing a definitive agreement within the next 45 days. Under the agreement, Optimi will serve as the sole supplier of GMP psilocybin drug candidates for ATMA, with future net sales generating shared revenue.

Additionally, Optimi commits to conducting any product development requirements in preparation for ATMA's Phase III clinical trial in 2025. ATMA will gain commercial access to Optimi's natural psilocybin drug candidate specifically for integration into its group administration protocol. This collaboration spans across significant territories including Canada, the United States, the United Kingdom, and the European Union, facilitating the treatment of Major Depressive Disorder (MDD) within ATMA's Group therapy framework.

Further, the combined supply agreement and group administration protocol will enable ATMA to provide the most cost-effective and accessible psilocybin-assisted therapy across its network of clinics and practitioners in North America, known as the ATMA CENA network.